Literature DB >> 8480957

The effectiveness of ovarian cancer screening. A decision analysis model.

M M Schapira1, D B Matchar, M J Young.   

Abstract

OBJECTIVE: To estimate the effectiveness of ovarian cancer screening with CA 125 and transvaginal sonography.
DESIGN: Decision analysis was used to examine the no-screen compared with the screen strategy.
SETTING: Estimates of cancer incidence, survival, and life expectancy were derived from population-based data and clinical series.
SUBJECTS: A cohort of 40-year-old women of all races and residing in the United States.
INTERVENTIONS: A one-time screening intervention. The criterion standard for diagnosis of ovarian cancer was evaluation with exploratory laparotomy. MAIN OUTCOME MEASURE: Average years of life expectancy gained by women in the screened group.
RESULTS: Screening for ovarian cancer with a combination of CA 125 and transvaginal sonography increases the average life expectancy in the population by less than 1 day.
CONCLUSIONS: Given the limited effect on overall life expectancy, it is unlikely that mass screening for ovarian cancer with CA 125 and transvaginal sonography would be an effective health policy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480957     DOI: 10.7326/0003-4819-118-11-199306010-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  4 in total

1.  Ovarian cancer screening was feasible but did not decrease incidence of index cancer or mortality.

Authors:  R Gluckman
Journal:  West J Med       Date:  2000-02

2.  Decision analysis for medical managers.

Authors:  J G Thornton; R J Lilford
Journal:  BMJ       Date:  1995-03-25

3.  Screening for ovarian cancer: is it appropriate?

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo.

Authors:  Lejla Hasanbegovic; Nedeljka Sljivo
Journal:  Mater Sociomed       Date:  2018-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.